A61L2430/18

CELL TRANSPLANTATION PRETREATMENT METHOD, CELL TRANSPLANTATION PRETREATMENT DEVICE, AND CELL TRANSPLANTATION PRETREATMENT UNIT
20220396755 · 2022-12-15 · ·

A cell transplantation pretreatment method, a cell transplantation pretreatment device, and a cell transplantation pretreatment unit are provided, which are capable of improving the efficiency of loading grafts into a transplantation device. The cell transplantation pretreatment method includes the steps of: transporting a cell group cultured in a culture recess to a pretreatment recess using a culture tray including a plurality of the culture recesses arranged according to a first arrangement, a pretreatment tray including a plurality of the pretreatment recesses arranged according to a second arrangement, and a transplantation device including a needle shaped portion having a tubular shape configured to allow entry and exit of a graft containing the cell group, the transplantation device including a plurality of the needle shaped portions arranged according to the second arrangement; and loading the cell groups simultaneously from the plurality of pretreatment recesses into the plurality of needle shaped portions.

MODIFIED 3D-PRINTED OBJECTS AND THEIR USES

Provided herein are methods which alter the mechanical and biological properties of polymeric materials. Also provided are compositions comprising the polymeric materials having said properties.

METHODS FOR TISSUE REGENERATION AND KITS THEREFOR

Methods are described herein for facilitating tissue regeneration in humans and other large organisms, and kits therefor. Application of an inhibitor of focal adhesion kinase (FAK) to injured tissue may reduce fibrosis and/or scarring during the wound healing process. Patient care for a large number of fibrotic diseases which affect organ function may be ameliorated by such treatment. Kits for application of the FAK inhibitor may include a hydrogel formulation encapsulating the FAK inhibitor.

Collagen compositions and uses for biomaterial implants

Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

DI-CUMYL PEROXIDE CROSSLINKING OF UHMWPE
20220325082 · 2022-10-13 ·

The inventions provide methods of manufacturing peroxide cross-linked and high temperature melted polymeric material, for example ultra-high molecular weight polyethylene (UHMWPE) containing vitamin E, total joint implants with high wear resistance, high oxidation resistance, and very low concentration of residual by-products, as well as products made thereby.

Method for promoting hair growth comprising implanting a tissue scaffold comprising CK-19 positive cells derived from Wharton's jelly mesenchymal stromal cells

A method of differentiating cells into CK19-positive cells capable of producing hair follicle-like and hair structure-like can include: providing a tissue scaffold; seeding cells into the scaffold, the cells being capable of differentiation; incubating the scaffold having the cells in a cell growth media; and incubating the scaffold having the cells in an osteogenic differentiation medium sufficient for CK19-positive cells to be generated in the scaffold. The tissue scaffold can be a decellularized Whartons' jelly matrix. The cell growth media excludes osteogenic differentiation components: dexamethasone, β-glycerophosphate, 1α,25-hydroxyvitamin D3, and ascorbic acid 2-phosphate. The osteogenic differentiation medium includes the osteogenic differentiation components. The cells can be mesenchymal cells, such as WJMSCs.

Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations

The present invention relates to a method for producing hair microfollicles comprising the steps of: a) providing de novo papillae, b) providing other cell populations selected from the group of fibroblasts, keratinocytes and melanocytes, and co-culturing the de novo papillae with at least one other cell population in non-adherent culture vessels. The present invention relates also to methods of producing de novo papillae usable in said method for producing hair microfollicles.

IN VITRO GROWTH METHOD FOR HAIR FOLLICULAR EPITHELIAL STEM CELLS

To provide means for efficient growth of epithelial cells capable of being used to manufacture regenerated hair follicle germs. Provided are a culture medium for growth of epithelial cells capable of being used to manufacture regenerated hair follicle germs, the culture medium comprising basal medium and at least (1) through (3), below: and a method for growing the epithelial cells using the culture medium: (1) at least one species of BMP inhibitor: (2) at least one species of fibroblast growth factor: and (3) at least one species of sonic hedgehog (SHH) and/or SHH agonist.

COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTS
20230270916 · 2023-08-31 ·

Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

CONTROLLED HYDROGEL DELIVERY OF FOCAL ADHESION KINASE INHIBITOR FOR DECREASED SCAR FORMATION

The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) formulated in a pullulan hydrogel The release profile of the FAK inhibitor can be adjusted according to the nature of the wound, e.g., excisional wounds, burn wounds, etc.